South Asia News: Nepal on Monday confirmed cases of Omicron sub-variant JN1. In a press release, the Ministry of Health and Population confirmed that seven cases relat
Explore the complexities of limited molecular genotyping availability, the importance of comprehensive testing, and challenges in accessing target therapies, including cost considerations, in real-world clinical practice.
Oxford Nanopore Technologies plc secured a £70 million (US$85 million) investment from Biomérieux SA. The investment comes on the back of a partnership formed between the two companies earlier in the year. The funds will support the development of products in Oxford Nanopore’s portfolio to serve in vitro diagnostics (IVD) markets.